# Infervision Medical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/infervision-medical-technology-co

- Industry: Healthcare IT
- Headquarters: Beijing, China
- Website: www.global.infervision.com
- Total disclosed funding: $75M
- Latest round: Series D (Jul 23, 2021)
- Investors on record: 18

## About

Infervision Medical Technology Co., Ltd. specializes in AI-driven medical imaging solutions that enhance diagnostic accuracy and improve workflows for healthcare providers.Infervision Medical Technology Co., Ltd. was founded in 2015 in Beijing, China. The company focuses on advanced imaging solutions for radiology. It has successfully raised a total of CNY 300.000 mn, with its latest funding round being Series B on July 23, 2021. This round included investments from Advantech Capital, Genesis Capital, Qiming Venture Partners, and Sequoia Capital. The company has completed 7 deals to date.Global Infervision specializes in advanced AI-driven imaging solutions, primarily focusing on radiology and medical imaging. The company’s flagship products include comprehensive software tools that enhance image analysis and interpretation, particularly in oncology and pulmonary disease detection. These solutions aim to streamline the workflow for healthcare professionals, enabling more accurate diagnoses and improved patient outcomes. Global Infervision’s technology is designed to assist radiologists by providing actionable insights from imaging data, ultimately addressing critical challenges in the timely detection of diseases. The company caters to a diverse client base, including hospitals, imaging centers, and healthcare providers across North America, Europe, and select markets in Asia.Global Infervision operates on a subscription-based revenue model, wherein clients pay an annual fee for access to their suite of imaging solutions. This structure allows for continuous updates and support, ensuring that healthcare facilities can utilize the latest advancements in AI technology without incurring significant upfront costs. Partnerships with healthcare institutions further enhance the company's reach and facilitate the integration of their solutions within existing medical workflows. The revenue from these subscriptions is bolstered through strategic collaborations with hospitals and healthcare networks, which often include training and support services as part of the package.In July 2021, Infervision Medical Technology Co., Ltd. raised CNY 300.000 mn in Series B funding to support its development in product R&D, talent recruitment, distribution channel growth, and international expansion. The company plans to launch new imaging solutions in 2022 while targeting market expansion into Europe and North America by 2023. This funding will facilitate advancements in their technology and increase their operational capabilities in these new markets.

## Funding rounds

- Series D, Jul 23, 2021 — Qiming Venture Partners, Goldman Sachs Asset Management, CCB Trust Co., Ltd., Toposcend Capital, Z-Park Fund, Zhongguancun Science City Capital
- Series D, Nov 24, 2020 — Co-Power Venture Capital, New Alliance Capital, Z-Park Fund, Zhongguancun Science City Capital
- Series C, Dec 7, 2018 — Hong Shan, CDH Investments, Haitong Leading Private Equity Fund Management, Genesis Capital, Advantech Capital, Xiang He Capital, TH Capital
- Series B, Feb 1, 2018, $48M — Hong Shan, Qiming Venture Partners, Genesis Capital, Advantech Capital
- Series B, Sep 21, 2017, $18M — Hong Shan, Qiming Venture Partners, Genesis Capital
- Series A, Jan 15, 2017, $7.2M — Hong Shan, GF Xinde Investment, Powercloud, Innoangel Fund
- Angel, Feb 1, 2016, $1.9M — Powercloud, Innoangel Fund

## Investors

- Powercloud (https://capitalatlas.ai/funds/powercloud) — Angel, Series A
- Innoangel Fund (https://capitalatlas.ai/funds/innoangel-fund) — Angel, Series A
- Hong Shan — Series A, Series B, Series C
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series A
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B, Series D
- Genesis Capital — Series B, Series C
- Advantech Capital (https://capitalatlas.ai/funds/advantech-capital) — Series B, Series C
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series C
- Haitong Leading Private Equity Fund Management (https://capitalatlas.ai/funds/haitong-leading-private-equity-fund-management) — Series C
- Xiang He Capital (https://capitalatlas.ai/funds/xiang-he-capital) — Series C
- TH Capital (https://capitalatlas.ai/funds/th-capital) — Series C
- Co-Power Venture Capital (https://capitalatlas.ai/funds/co-power-venture-capital) — Series D
- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Series D
- Z-Park Fund (https://capitalatlas.ai/funds/z-park-fund) — Series D
- Zhongguancun Science City Capital (https://capitalatlas.ai/funds/zhongguancun-science-city-capital) — Series D
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series D
- CCB Trust Co., Ltd. — Series D
- Toposcend Capital (https://capitalatlas.ai/funds/toposcend-capital) — Series D